This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (52)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Movement Disorders  • Parkinson Disease/ Parkinsonian Disorders  • Women's Health  • Women's Health, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Lillian J. Currie, PhD, RN; Madaline B. Harrison, MD; Joel M. Trugman, MD; James P. Bennett, MD, PhD; G. Frederick Wooten, MD

Arch Neurol. 2004;61:886-888.

Background  Although estrogen therapy has been associated with improved cognitive functioning, a reduced risk of dementia in women with Parkinson disease (PD), and a decreased risk of Alzheimer disease, estrogen therapy has not affected the risk of PD per se.

Objective  To determine whether postmenopausal women with PD differed from control subjects with regard to estrogen exposure.

Design, Setting, and Patients  A case-control design was used, abstracting questionnaire data obtained via interview from 133 female PD cases and 128 female controls during routine outpatient clinic visits in 1999 at a mid-Atlantic tertiary care referral center. There were 140 subjects (68 PD cases and 72 controls) who met the inclusion criteria.

Main Outcome Measure  Use of postmenopausal estrogen therapy.

Results  More women in the control group than in the PD group took postmenopausal estrogen (36 [50%] of 72 women vs 17 [25%] of 68 women; P<.003), and women who had taken postmenopausal estrogen were less likely to develop PD than those who had not (odds ratio, 0.40 [95% confidence interval, 0.19-0.84]; P<.02). Among PD cases only, postmenopausal estrogen use was not associated with age of onset.

Conclusion  Postmenopausal estrogen therapy may be associated with a reduced risk of PD in women.

From the Department of Neurology, School of Medicine, University of Virginia Health System, Charlottesville.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Diet, Urate, and Parkinson's Disease Risk in Men
Gao et al.
Am J Epidemiol 2008;167:831-838.
ABSTRACT | FULL TEXT  

Management of Parkinson's disease in older women
Price and Shulman
Menopause Int 2008;14:38-39.
ABSTRACT | FULL TEXT  

Differential Effects of Black versus Green Tea on Risk of Parkinson's Disease in the Singapore Chinese Health Study
Tan et al.
Am J Epidemiol 2008;167:553-560.
ABSTRACT | FULL TEXT  

Increased risk of parkinsonism in women who underwent oophorectomy before menopause
Rocca et al.
Neurology 2008;70:200-209.
ABSTRACT | FULL TEXT  

Gender differences in Parkinson's disease
Haaxma et al.
J. Neurol. Neurosurg. Psychiatry 2007;78:819-824.
ABSTRACT | FULL TEXT  

Estrogen Receptor beta in Health and Disease
Imamov et al.
Biol. Reprod. 2005;73:866-871.
ABSTRACT | FULL TEXT  

17{alpha}-Estradiol: A Brain-Active Estrogen?
Toran-Allerand et al.
Endocrinology 2005;146:3843-3850.
ABSTRACT | FULL TEXT  

Effect of reproductive factors and postmenopausal hormone use on the risk of Parkinson disease
Popat et al.
Neurology 2005;65:383-390.
ABSTRACT | FULL TEXT  

Reflections on the Discovery and Significance of Estrogen Receptor {beta}
Koehler et al.
Endocr. Rev. 2005;26:465-478.
ABSTRACT | FULL TEXT